Septerna, Inc. has reported a notable stock sale by its director, Alan Ezekowitz. On November 11, 2026, Ezekowitz sold 100,000 shares of the company, valued at approximately $5.2 million. This transaction is significant as it reflects ongoing activity within the company and the broader pharmaceutical preparations industry.

Septerna, Inc., classified under the SIC code 2834, specializes in pharmaceutical preparations. The company is publicly traded on the Nasdaq under the ticker SEPN. It is categorized as a non-accelerated filer, a smaller reporting company, and an emerging growth company. The company is headquartered in South San Francisco, California.

The recent SEC filing details that Ezekowitz acquired the shares through open market purchases in March 2025. The filing states, "The securities to be sold were acquired upon the vesting of open market purchases during the period of 3/4/2025 through 3/7/2025." The sale was executed through Morgan Stanley Smith Barney LLC, a well-known financial services firm.

This stock sale may affect various stakeholders, including investors and analysts monitoring Septerna's performance. The transaction could signal confidence in the company's future or a strategic move by Ezekowitz, which might influence market perceptions.

The filing does not say what happens next regarding further transactions or company announcements.